Join our daily newsletter At The Bell to receive exclusive market insights
- Medlab Clinical (MDC) has formally launched the NanaBis Observation Study in Australia
- NanaBis is a cannabis-based pain treatment drug and is also being used to investigate cancer pain management
- The study is looking to find 2000 patients to help assess the drug over 12 months
- On market close, Medlab is up 3.17 per cent and is trading at 32.5¢ apiece
Medlab Clinical (MDC) has formally launched the NanaBis Observation Study in Australia.
NanaBis is a cannabis-based pain treatment drug and is also being used to investigate cancer pain management.
Human Ethics has approved the observational study to be assessed in real-world use. The study is looking to find 2000 Australian patients in a hospital or medical setting to assess the drug over 12 months.
Out of the patients, Medlab expects approximately 700 of them will be diagnosed with cancer pain. Patients will be offered NanaBis at a reduced price and doctors will be compensated for their time on a monthly per-patient basis.
The recently announced commercial agreement with Tasmanian Alkaloids, allows Medlab to upscale manufacturing to cater for increased demand.
“Medlab will be working closely with healthcare professionals to provide educational tools to better understand NanaBis as a treatment option for patients living with chronic pain,” CEO Sean Hall said.
“Participating patients will have access to medical cannabis at a significantly reduced price,” he added.
On market close, Medlab is up 3.17 per cent and is trading at 32.5¢ apiece.
